Syntara Limited ( ($AU:SNT) ) has shared an announcement. Syntara Limited reported a strong September quarter marked by clinical progress across its pipeline ...
For that indication, Rytelo is dosed at 7.1 mg/kg administered as an intravenous infusion every four weeks. Thrombocytopenia ...
A 55-CpG DNA methylation signature developed from bone marrow samples and validated in an independent cohort appears to ...
A Stanford Medicine study that looked at outcomes of cancer patients identified with mental health disorders found ...
Geron said on Wednesday it would discontinue a late-stage trial testing its treatment for patients with a form of rare blood cancer.
Oct 28 () - Geron said on Wednesday it would discontinue a late-stage trial testing its treatment for patients with a form of rare blood cancer. The drug, branded as Rytelo, was being evaluated as ...
Fundamental research conducted in a University of Dundee laboratory that provided the basis for a novel protein degradation ...
Tetsuya Chiba creator of Ashita no Joe died at 87 from myelodysplastic syndrome Here is what we know about his death work and ...
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of TALZENNA® (talazoparib) in ...
Oral vitamin C improved OS in patients with CCUS or lower-risk myeloid malignancies in the EVITA trial despite missing the clonal growth primary end point. Although the phase 2 EVITA trial ...
The FDA previously approved FoundationOne CDx, which uses a tumor tissue sample, and FoundationOne Liquid CDx, which uses a ...
Abbott’s next-gen Oncodetect molecular residual disease (MRD) test detects traces of circulating tumor DNA in a patient’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results